FDA Animal Efficacy Rule Drops Superiority Requirement For New Agents
Executive Summary
FDA's final rule allowing drug approvals based on animal efficacy studies will permit more than one drug to be approved for an indication without a clear demonstration of superiority over existing products
You may also be interested in...
FDA Moving Beyond Animal Rule To Animal Guidance With November Workshop
Focus will be on addressing regulatory challenges faced in developing countermeasures to chemical, biological and radiological threats.
FDA Panel Finds Animal Models Predict Human Response To HGS Anthrax Drug
Animal model results for Human Genome Sciences' raxibacumab are predictive of the biologics' ability to treat inhalation anthrax in humans, FDA's Anti-Infective Drugs Advisory Committee concluded Oct. 27, but FDA should request more evidence on whether the monoclonal antibody adds benefit to treatment with antibiotics alone
FDA Panel Finds Animal Models Predict Human Response To HGS Anthrax Drug
Animal model results for Human Genome Sciences' raxibacumab are predictive of the biologics' ability to treat inhalation anthrax in humans, FDA's Anti-Infective Drugs Advisory Committee concluded Oct. 27, but FDA should request more evidence on whether the monoclonal antibody adds benefit to treatment with antibiotics alone